Table 1 Baseline characteristics by allocation group (intention-to-treat analysis set)
From: Bronchiectasis Information and Education: a randomised, controlled feasibility trial
|  | Control group (n = 30) | Intervention group (n = 32) | Total (N = 62) |
|---|---|---|---|
Gender | |||
 Female | 18 (60%) | 20 (62.5%) | 38 (61%) |
 Male | 12 (40%) | 12 (37.5%) | 24 (39%) |
Age (years) | |||
 Median (range) | 65 (34–81) | 65 (18–81) | 65 (18–81) |
FEV1 (% predicted) | |||
 Median (range) | 75 (21–120) | 67 (10–110) | 68 (10–120) |
BSI scorea | |||
 Median (range) | 6 (2–15) | 7 (2–14) | 6 (2–15) |
BSI severity group | |||
 Mild (score 0–4) | 9 (30%) | 13 (41%) | 22 (35%) |
 Moderate (score 5–8) | 14 (47%) | 13 (41%) | 27 (44%) |
 Severe (score > 8) | 7 (23%) | 6 (19%) | 13 (21%) |
Time since diagnosis (years) | |||
 Median (range) | 6 (0.5–70) | 15 (0.25–70) | 10 (0.25–70) |
  > 10 | 9 (30%) | 17 (53%) | 26 (42%) |
  > 5 ≤ 10 | 5 (17%) | 2 (6%) | 7 (11%) |
  > 1 ≤ 5 | 10 (33%) | 6 (19%) | 16 (26%) |
  > 6 months ≤ 1 year | 5 (17%) | 3 (9%) | 8 (13%) |
  ≤ 6 months | 1 (3%) | 3 (9%) | 4 (6%) |
Bronchiectasis aetiology | |||
 Idiopathic | |||
 Post-infection | 12 (40%) | 10 (31%) | 22 (35%) |
 Secondary to chronic asthma/COPD | 6 (20%) | 11 (34%) | 17 (27%) |
 Immune deficiency associated | 7 (23%) | 5 (16%) | 12 (19%) |
 Otherb | 2 (7%) 3 (10%) | 1 (3%) 5 (16%) | 3 (5%) 8 (13%) |
Exacerbations per year | |||
  < 3 | 13 (43%) | 10 (31%) | 23 (37%) |
  ≥ 3 | 17 (57%) | 22 (69%) | 39 (63%) |
Use of home intravenous antibiotics | |||
 Y | 8 (27%) | 15 (47%) | 23 (37%) |
 N | 22 (73%) | 17 (53%) | 39 (63%) |
Clinic attended | |||
 Specialist | 28 (93%) | 30 (94%) | 58 (94%) |
 General | 2 (7%) | 2 (6%) | 4 (6%) |
Prior bronchiectasis hospital admissions | |||
 Y | 16 (53%) | 25 (78%) | 41 (66%) |
 N | 14 (47%) | 7 (22%) | 21 (34%) |
Sputum microbiology | |||
Pseudomonas aeruginosa | 8 (27%) | 9 (28%) | 17 (27%) |
 Otherc | 8 (27%) | 11 (34%) | 19 (31%) |
 Not colonised | 13 (43%) | 11 (34%) | 24 (39%) |
 No samples | 1 (3%) | 1 (3%) | 2 (3%) |
Drug treatments | |||
 Azithromycin | 10 (33%) | 18 (56%) | 28 (45%) |
 Nebulised antibiotics | 6 (20%) | 3 (9%) | 9 (15%) |
Devices used to access Internet/resource | |||
 Mobile | 2 (7%) | 8 (25%) | 10 (16%) |
 Tablet | 13 (43%) | 10 (31%) | 23 (72%) |
 PC/laptop | 28 (93%) | 28 (88%) | 56 (90%) |
 No access | 0 | 1 (3%) | 1 (2%) |
Previous bronchiectasis information seeking | |||
 None | 9 (30%) | 5 (16%) | 14 (23%) |
 Paper | 9 (30%) | 14 (44%) | 23 (37%) |
 Online | 14 (47%) | 16 (50%) | 30 (48%) |
 In person | 4 (13%) | 3 (9%) | 7 (11%) |